Loading...
NPI 1922072586 · Idaho Falls, ID · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Eric Romriell is a ophthalmology physician provider located in Idaho Falls, Idaho. This profile covers 20 Medicare and 1 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Eric Romriell |
| Address | 2025 E 17th St |
| City | Idaho Falls |
| State | ID |
| ZIP | 83404 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | February 13, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $1.7M |
| Medicaid | $1.1K |
ERIC ROMRIELL’s Medicare billing is dominated by intravitreal drug therapy and associated injection procedures, with J0178 (aflibercept) accounting for 52.7% of Medicare revenue ($876.2K) and 1.3K claims, supplemented by 67028 (procedure-level intravitreal injection) at 10.3% ($170.6K, 2.1K claims) and J2777 (faricimab) at 9.0% ($149.6K, 5.2K claims). This code mix — high-volume anti-VEGF drug billing plus a high count of injection procedure codes — indicates an outpatient retina practice model focused on in-office pharmacologic treatment of posterior-segment disease, supported by imaging codes appearing elsewhere on the file.
Revenue concentration is high on Medicare: the precomputed top three Medicare codes account for 71.9% of this provider’s total Medicare revenue, concentrated around J0178 (52.7%), 67028 (10.3%), and J2777 (9.0%). With total Medicare revenue of $1.7M, this concentration signals material dependence on a narrow set of drug and injection codes to drive top-line Medicare receipts.
Medicaid activity is negligible compared with Medicare: total Medicaid revenue is $1.1K and is entirely driven by a single code, 92201 (50 claims, $21 avg paid/claim, $1.1K), which represents 100.0% of the provider’s Medicaid revenue. That single-code Medicaid footprint, ranked #1 of 2 in-state, shows the provider is effectively Medicare-focused rather than a dual-payer operator at scale.
Competitive standing on key Medicare codes is mixed: J0178 ranks #1030 of 3204 nationally (68th percentile; typical, unremarkable volume), 67028 ranks #377 of 4255 (91th percentile; typical, unremarkable volume), and J2777 ranks #1511 of 2039 (26th percentile; typical, unremarkable volume). In other words, the provider posts typical-to-high national volumes for core injection services but is not a dominant national leader on most billed codes.
Several codes show markedly elevated relative activity that differentiates this practice: J7312 (dexamethasone intravitreal implant) ranks #20 of 492 (96th percentile; notably above typical national volume), J7999 (compounded drug) ranks #19 of 1333 (99th percentile; notably above typical national volume), and 92134 (retinal OCT) ranks #574 of 26868 (98th percentile; extreme outlier). These high-percentile signals suggest unusually heavy use of certain implants, compounded medications, and retinal imaging versus national peers.
Office evaluation-and-management activity is also elevated for specific codes: 99213 appears as 824 claims with $46.1K revenue and ranks #10054 of 457151 (98th percentile; notably above typical national volume). This supports a picture of a high-throughput clinic that pairs frequent procedure visits with routine E/M visits for established patients.
Provider tenure is long-standing: the NPI was enumerated on 2006-02-13 (~20 years ago), indicating an established presence in the market that could support the sustained referral patterns and patient volumes reflected in the Medicare billing profile. Such longevity is consistent with the concentrated, procedure-heavy revenue mix observed.
Operational and contracting implications: because $1.7M of revenue comes from Medicare while Medicaid totals only $1.1K, this practice is effectively single-payer in scale and financially sensitive to Medicare payment rates and the mix of high-revenue drugs (e.g., J0178 at $691 avg paid/claim). Payers and network managers should note the practice’s reliance on a small set of high-impact codes (top-3 = 71.9% of Medicare revenue) when evaluating reimbursement arrangements, utilization management, or network adequacy for retinal injection services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
20 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 1,270 | $690 | $876.2K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 2,060 | $80 | $170.6K |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 5,160 | $30 | $149.6K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 640 | $160 | $99.4K |
| J7999 | Compounded drug, not otherwise classified | 1,500 | $60 | $91.2K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,660 | $30 | $69.1K |
| J2778 | Injection, ranibizumab, 0.1 mg | 360 | $180 | $62.1K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 820 | $60 | $46.1K |
| 92235 | The provider uses a special dye, fluorescein that causes the blood vessels in the one or both eyes to stand out in photographic images taken with the use of multiframe timing, or serial images, taken… | 390 | $90 | $34.6K |
| 67210 | The provider destroys a lesion of the retina using a laser beam that heats up the tissue. | 60 | $370 | $23.3K |
Showing 1–10 of 20
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 20 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
20 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 5 | 20 | 670 | $690 | $541.7K |
| J2777 | 11 | 10 | 8,640 | $30 | $454.7K |
| J2778 | 5 | 10 | 1,190 | $180 | $352.5K |
| J7312 | 2 | 10 | 640 | $160 | $80.5K |
| 67028 | 3 | 30 | 470 | $90 | $66.6K |
| 67036 | 5 | 10 | 20 | $1,040 | $33.3K |
| 67210 | 1 | 10 | 60 | $370 | $23.3K |
| J7999 | 1 | 20 | 200 | $70 | $18.9K |
| 67228 | 1 | 10 | 60 | $220 | $12.8K |
| 92235 | 1 | 10 | 80 | $90 | $12.6K |
Showing 1–10 of 20
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 92201 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 50 | $20 | $1.1K |
How this provider's Medicaid billing volume and revenue compare to other Idaho providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Idaho median
1 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 92201 | The provider performs an extended ophthalmoscopy, typically with an indirect ophthalmoscope which utilizes a bright light and a hand–held indirect lens rather than the common hand–held one–piece… | 1 | 10 | 40 | $20 | $660 |
Other providers in the same ZIP code as Eric Romriell, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.